Navigation Links
Single vaccines to protect against both rabies and Ebola
Date:8/25/2011

PHILADELPHIAResearchers from Thomas Jefferson University, among other institutions, including the National Institute of Allergy and Infectious Diseases, have developed single vaccines to protest against both rabies and the Ebola virus.

Successfully tested in mice, these bivalent vaccines have several advantages over other Ebola candidates that could help speed up development for use in humans and primates. It's built on the same platform as the already approved and financially viable rabies vaccine, and it protects at-risk populations against two viruses, not just one, making it an effective and ideal public health tool.

"Many Ebola vaccine candidates have been proven effective, but none are close to licensure," said Matthias Schnell, Ph.D., director of the Jefferson Vaccine Center. "One of the challenges is the market: There's rather limited incentive in creating a vaccine for Ebola. But these vaccines could change that."

The findings were published ahead of print online August 17 in the Journal of Virology.

The Ebola virus belongs to the Filoviridae family and is comprised of five distinct species. The Zare, Sudan and Bundibugyo species have been associated with large Ebola hemorrhagic fever outbreaks in Africa. According to the World Health Organization, more than a thousand people have died from the virus since it was discovered in 1976.

"Rabies still poses a health threat for people worldwide, and is especially devastating in developing nations where a post exposure treatment is often not available. And Ebola still exists in parts of Central Africa and is also a chief bioterrorism concern worldwide," said Dr. Schnell, who is also a Professor in the Department of Microbiology and Immunology at Thomas Jefferson University. "You can protect these people from two very lethal diseases in an area where they don't have the best access to medical care."

The purpose of this study was to identify novel vaccine candidates for Ebola with a maximum potential of licensure and utilization.

Researchers generated a chemically inactivated and live rabies virus expressing the Ebola Zare species glycoprotein using a reverse genetics system based on the commonly-used rabies vaccine. Immunizations with those vaccines, the researchers found, induced immunity against each virus and conferred protection from both viruses in mice.

Piggy backing, in a sense, on the rabies vaccine could accelerate development of vaccines that protects against Ebola because of the advanced state of the rabies vaccine's safety, production and distribution, according to Schnell.

"After the vaccine has been tested in primates and eventually humans, this new vaccine could kill the proverbially two birds with one stone," he said.

There are implications for nonhumans, toogorillas, in particular. The Ebola virus has eradicated thousands of gorillas, prompting the World Conservation Union to raise their status to "critically endangered" in 2007, the first time a mammal has become critically endangered as a direct result of disease. Vaccinations, though challenging, could stall those deaths.

What's more, several human outbreaks have been attributed to primate interaction or handling, so providing a vaccine for our closest relative could minimize that risk.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-6300
Thomas Jefferson University
Source:Eurekalert  

Related medicine news :

1. Single flexible sigmoidoscopy screening associated with reduced colorectal cancer
2. Single traumatic brain injury may prompt long-term neurodegeneration
3. Single Reading Cant Gauge Blood Pressure Control: Study
4. Single moms entering midlife may lead to public health crisis
5. Single bioptic telescope for low vision driving may not obscure road view of second eye
6. Single Gene Linked to Evolution of Human Brain
7. Advanced technology reveals activity of single neurons during seizures
8. Single gene defect causes brain tumor
9. See how they grow: Monitoring single bacteria without a microscope
10. Cancer in a single catastrophe
11. Scientists Aim for Test That Spots Single Cancer Cell in Blood Sample
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Single vaccines to protect against both rabies and Ebola
(Date:1/16/2017)... , ... January 16, 2017 , ... St. Louisans are well-aware of the following facts ... This year’s influenza shot seems to be having no effect on keeping this particularly ... half of the people around are coughing, sneezing, or sniffling , These ...
(Date:1/16/2017)... ... ... San Francisco dentist, Dr. Ben Amini , the founder at CitiDent, ... capable of taking digital impressions of teeth and gums. Conventional bite impressions have lagged ... , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are being ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an ... new avenues for purchase. , The 2017 edition has wide jaws that will accommodate ... older boomers as well as diabetics. This handle is reinforced for extra strength when pressing ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing Gym is ... wraps up on the 14,000+ square foot climbing gym, the owners anticipate to open ... in New Jersey and two in New York. With this being its first location ...
(Date:1/14/2017)... ... , ... "TransFreeze Volume 3 is a self animating masking transition which allows users to reveal ... said Christina Austin - CEO of Pixel Film Studios. , TransFreeze Volume 3 provides ... clip to the next. , To use “Cut-Out First” presets, choose a video ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... Eli Lilly and Company (NYSE: ... ) announced today that the U.S. Food and Drug ... new drug application (NDA) for investigational baricitinib, a once-daily ... rheumatoid arthritis (RA). The NDA for baricitinib was submitted ... FDA extended the action date to allow time to ...
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
Breaking Medicine Technology: